Altrubio
Immunology & Inflammation Therapeutics · Biotechnology
Overview
AltruBio. Developing safer, more durable treatments to improve the lives of patients.
Key facts
These are the key facts about Altrubio on Alion as of Nov 13, 2026. Altrubio is headquartered in Taipei, Taiwan. The latest round is Series B of $225M, announced in 2024.
- Headquarters
- Taipei, TaiwanAlion company profile, updated Sep 29, 2026
- Total raised
- $225MSum of 1 equity round Alion knows
- Latest round
- Series B · $225M · May 21, 2024Press report · menafn.com
Funding and backers
Total raised
$225M
1 round on record
Latest round
$225M
Series B · May 2024 · 2 yr ago
Backers
2
RA Capital Management, aMoon
The money's age
Long since its last round
29 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 21, 2024
Raised a round Series B $225M · led by BVF Partners LP · menafn
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | May 2024 | $225M | BVF Partners LP lead, RA Capital Management, Cormorant Asset | menafn |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
We are using a precision approach to develop therapies designed to transform the lives of patients with immune-mediated diseases.
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
SymPhysis Medical specializes in medical technology designed to improve the lives of patients with chronic conditions.
Replicate Bioscience is pioneering novel self-replicating RNA (srRNA) technology to enable more treatment opportunities for more people.
You are leaving Spyre. If you would like to proceed, click the link to continue. https://twitter.com/.
CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
Financials
Total raised
$225M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2024 | $225M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
aMoonVia a fund
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Report
AltruBio: $225 Million Raised To Develop Novel Therapeutics For Treating Immunological Diseases With Unmet Medical Needs
AltruBio, a clinical stage biotechnology company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, announced an oversubscribed Series B financing of up to $225 million.
Read more
Report
Immune checkpoint enhancer biotech AltruBio raises $225m
Immune checkpoint enhancer biotech AltruBio raises $225m to support phase 2 trials of its PSGL-1-targeted drug for ulcerative colitis.
Read more
Report
AltruBio raises $225 million to develop ulcerative colitis drug and other immune checkpoint enhancers
AltruBio's $225 million Series B is the latest example of intense investor interest in immunology-focused companies.
Read more
Report
AltruBio, after tweaking checkpoint drug, raises $225M for midphase ulcerative colitis program
Read more
Report
Altrubio Secures Up To $225M Oversubscribed Series B Financing To Advance The Clinical Development Of Novel Immune Checkpoint Enhancer Program
Altrubio Secures Up To $225M Oversubscribed Series B Financing To Advance The Clinical Development Of Novel Immune Checkpoint Enhancer Program. Financing led by BVF Partners LP, with participation from new investors RA Capital Management, Cormorant Asset
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Taipei
Taiwan
HQ
Taipei, Taiwan
9F.-1, No. 508, Sec. 7, Zhongxiao E. Rd.,, Nangang Dist., Taipei, Taiwan 115206
How to cite this page
Alion, "Altrubio: key facts", as of Nov 13, 2026. https://alion.io/company/altrubio
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0